REGENXBIO Inc. (NASDAQ:RGNX) Director Donald J. Hayden, Jr. sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $24.95, for a total transaction of $499,000.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at approximately $499,000. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shares of REGENXBIO Inc. (RGNX) traded up 1.43% on Thursday, hitting $24.80. 249,197 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $20.30 and its 200 day moving average is $19.76. REGENXBIO Inc. has a 12 month low of $12.81 and a 12 month high of $25.00. The firm’s market cap is $766.17 million.

REGENXBIO (NASDAQ:RGNX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.34. The firm had revenue of $6.56 million during the quarter. REGENXBIO had a negative net margin of 839.87% and a negative return on equity of 38.74%. On average, equities analysts predict that REGENXBIO Inc. will post ($2.87) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Donald J. Hayden, Jr. Sells 20,000 Shares of REGENXBIO Inc. (RGNX) Stock” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/09/07/donald-j-hayden-jr-sells-20000-shares-of-regenxbio-inc-rgnx-stock.html.

RGNX has been the topic of a number of research reports. Chardan Capital upped their price target on shares of REGENXBIO from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research lowered shares of REGENXBIO from a “buy” rating to a “hold” rating in a research note on Thursday, August 17th. Evercore ISI initiated coverage on shares of REGENXBIO in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, BidaskClub upgraded shares of REGENXBIO from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. REGENXBIO presently has a consensus rating of “Buy” and an average price target of $37.00.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Redmile Group LLC increased its stake in shares of REGENXBIO by 35.4% in the second quarter. Redmile Group LLC now owns 1,718,671 shares of the biotechnology company’s stock worth $33,944,000 after purchasing an additional 449,540 shares in the last quarter. Perceptive Advisors LLC increased its stake in shares of REGENXBIO by 8.9% in the first quarter. Perceptive Advisors LLC now owns 1,396,244 shares of the biotechnology company’s stock worth $26,947,000 after purchasing an additional 113,958 shares in the last quarter. JPMorgan Chase & Co. increased its stake in shares of REGENXBIO by 4.3% in the second quarter. JPMorgan Chase & Co. now owns 1,226,835 shares of the biotechnology company’s stock worth $24,230,000 after purchasing an additional 51,041 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of REGENXBIO by 10.3% in the second quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock worth $21,379,000 after purchasing an additional 100,944 shares in the last quarter. Finally, Citadel Advisors LLC increased its stake in shares of REGENXBIO by 65.4% in the second quarter. Citadel Advisors LLC now owns 926,176 shares of the biotechnology company’s stock worth $18,292,000 after purchasing an additional 366,289 shares in the last quarter. Hedge funds and other institutional investors own 73.23% of the company’s stock.

About REGENXBIO

REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.

Insider Buying and Selling by Quarter for REGENXBIO (NASDAQ:RGNX)

Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.